QuidelOrtho (QDEL) to Release Earnings on Wednesday

QuidelOrtho (NASDAQ:QDEL) is expected to announce its Q4 2025 results after the market closes on Wednesday, February 11th. Analysts expect the company to announce earnings of $0.54 per share and revenue of $699.7950 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 5:00 PM ET.

QuidelOrtho (NASDAQ:QDEL) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.51 by $0.29. QuidelOrtho had a positive return on equity of 5.75% and a negative net margin of 42.53%.The company had revenue of $699.90 million during the quarter, compared to analysts’ expectations of $667.45 million. During the same quarter in the previous year, the business earned $0.85 EPS. QuidelOrtho’s revenue was down 3.7% compared to the same quarter last year. On average, analysts expect QuidelOrtho to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

QuidelOrtho Stock Up 1.2%

NASDAQ:QDEL opened at $27.98 on Wednesday. The company has a market cap of $1.90 billion, a price-to-earnings ratio of -1.64 and a beta of 0.68. QuidelOrtho has a twelve month low of $19.50 and a twelve month high of $44.68. The company has a current ratio of 1.78, a quick ratio of 0.98 and a debt-to-equity ratio of 1.23. The stock has a fifty day simple moving average of $29.49 and a 200-day simple moving average of $27.65.

Analyst Ratings Changes

QDEL has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of QuidelOrtho in a report on Thursday, January 22nd. JPMorgan Chase & Co. reduced their target price on shares of QuidelOrtho from $26.00 to $22.00 and set an “underweight” rating on the stock in a research report on Friday, November 7th. Citigroup reaffirmed a “neutral” rating and set a $33.00 price target (down previously from $40.00) on shares of QuidelOrtho in a research note on Tuesday, October 7th. Zacks Research raised QuidelOrtho from a “strong sell” rating to a “hold” rating in a research note on Tuesday, January 13th. Finally, UBS Group upped their target price on QuidelOrtho from $31.00 to $35.00 and gave the stock a “neutral” rating in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $39.00.

Insider Transactions at QuidelOrtho

In other news, CEO Brian J. Blaser bought 23,500 shares of the stock in a transaction on Wednesday, November 19th. The stock was bought at an average cost of $21.34 per share, for a total transaction of $501,490.00. Following the completion of the purchase, the chief executive officer directly owned 29,533 shares in the company, valued at approximately $630,234.22. The trade was a 389.52% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Joseph M. Busky purchased 4,770 shares of the business’s stock in a transaction on Monday, November 24th. The stock was purchased at an average cost of $26.06 per share, for a total transaction of $124,306.20. Following the completion of the acquisition, the chief financial officer directly owned 6,920 shares of the company’s stock, valued at approximately $180,335.20. The trade was a 221.86% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 29,390 shares of company stock worth $657,340 over the last 90 days. Company insiders own 0.79% of the company’s stock.

Institutional Trading of QuidelOrtho

A number of institutional investors and hedge funds have recently added to or reduced their stakes in QDEL. Invesco Ltd. increased its holdings in shares of QuidelOrtho by 87.0% in the third quarter. Invesco Ltd. now owns 2,906,763 shares of the company’s stock valued at $85,604,000 after purchasing an additional 1,352,503 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of QuidelOrtho by 14.0% during the third quarter. Dimensional Fund Advisors LP now owns 2,859,455 shares of the company’s stock worth $84,208,000 after purchasing an additional 350,636 shares during the period. State Street Corp boosted its position in QuidelOrtho by 23.3% in the second quarter. State Street Corp now owns 2,700,940 shares of the company’s stock valued at $77,841,000 after buying an additional 510,291 shares during the last quarter. Newtyn Management LLC increased its holdings in QuidelOrtho by 58.3% in the 3rd quarter. Newtyn Management LLC now owns 2,700,000 shares of the company’s stock worth $79,515,000 after buying an additional 994,332 shares during the period. Finally, Paradigm Capital Management Inc. NY raised its position in QuidelOrtho by 59.0% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 746,290 shares of the company’s stock worth $21,508,000 after buying an additional 276,790 shares during the last quarter. Institutional investors and hedge funds own 99.00% of the company’s stock.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.